Pomalyst
(Pomalidomide)ApprovedSmall molecule
Pomalidomide is used to treat multiple myeloma, a type of blood cancer affecting bone marrow cells. It works by helping the immune system fight cancer cells and by directly slowing cancer cell growth.[2] Pomalyst is currently approved and in use across 33 indications[4].[1]
Pomalyst is one of 443 small molecule programs targeting Primary Myelofibrosis. It is currently in Approved.
33
Indications
253
Total Trials
56
Active Trials
442
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
6
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 33 indications
Competition
Competitive Landscape
332 competitors in Treatment
#DrugCompanyPhaseTrials
1Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Dexilant
TakedaPreclinical
Theo-Dur
PfizerPreclinical
Emtriva
GileadPreclinical
Foscavir
CClinigen, Inc.
Preclinical
Valium
Akero TherapeuticsPreclinical
Barhemsys
Tibotec Pharmaceuticals, IrelandPreclinical
Norpramin
VValidus Pharmaceuticals
Preclinical
Lotemax
PPharmos
Preclinical
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma116 trials
Show 113 more trials
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Withdrawn·—·Phase 2·NCT03841565
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Recruiting·—·Phase 2·NCT04508790·29 enrolled
Pomalidomide11 trials
Show 8 more trials
Dexamethasone9 trials
Show 6 more trials
Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans
Unknown status·IInstituto de Seguridad y Servicios Sociales de los Trabajadores del Estado·Phase 2·NCT03601624·18 enrolled
Ixazomib + Pomalidomide + Dexamethasone In MM
Active, not recruiting·—·Phase 1/2·NCT04094961·52 enrolled
AL amyloidosis6 trials
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Recruiting·—·Phase 2·NCT06342466·40 enrolled
Show 3 more trials
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
Completed·—·Phase 1/2·NCT01570387·27 enrolled
Lenalidomide3 trials
47 more indications
Central Nervous System Lymphoma2 trials
Treatment2 trials
Lymphoma2 trials
Amyloidosis2 trials
Myelofibrosis2 trials
Kaposi Sarcoma2 trials
Mantle Cell Lymphoma1 trial
Maximum Tolerated Dose1 trial
Waldenstrom macroglobulinemia1 trial
Maintenance Treatment1 trial
Advanced Malignancies1 trial
Myelodysplastic Syndrome1 trial
Soft Tissue Sarcoma1 trial
Primary Brain Tumor1 trial
Relapsed/Refractory1 trial
Central Nervous System1 trial
Marizomib Central Nervous System (CNS)
Withdrawn·—·Phase 2·NCT05050305
Central Nervous System Tumor1 trial
Blood Cancer1 trial
Toxicity1 trial
Renal insufficiency1 trial
Anti-PD-1 Antibody1 trial
Interstitial Lung Disease1 trial
Diffuse Large B-Cell Lymphoma1 trial
Idiopathic Pulmonary Fibrosis1 trial
Plasma Cell Leukemia1 trial
Combination Therapy1 trial
Myeloproliferative Neoplasms1 trial
TED1 trial
Sickle Cell Disease1 trial
Hereditary Hemorrhagic Telangiectasia1 trial
Immunodeficiency1 trial
Macroglobulinemia1 trial
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
Terminated·—·Phase 1·NCT01078974·7 enrolled
Recurrent Multiple Myeloma1 trial
Myeloma1 trial
Multiple Myeloma (MM)1 trial
Relapsed or Refractory Multiple Myeloma1 trial
Relapsed or Refractory Multiple Myeloma (RRMM)1 trial
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma
Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 3·NCT06615479·440 enrolled
Refractory Plasma Cell Myeloma1 trial
Regulatory
FDA Approval Timeline[5]
Feb 8, 2013
POMALYST
NDA NDA204026
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Pomalyst drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Pomalidomide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
Patent Landscape[6]
Patent Cliff
May 19, 2030
Earliest patent expiration — generic entry possible after this date
Patent #Expires
10555939May 19, 2030
9993467May 19, 2030
9993467*PEDNov 19, 2030
10555939*PEDNov 19, 2030
8828427Jun 21, 2031
1 more patents
8828427*PEDDec 21, 2031